• Completes second acquisition in FY22

Bengaluru, August 03, 2021

Healthium, a global player in medical devices, today announced the successful acquisition of the AbGel gelatin sponge business from Mumbai-based Shri SGK Labs, adding to its product portfoliofocused on surgical and post-surgical care. Earlier this financial year, the Company had acquired VitalCare Group in U.K to grow its urology portfolio and expand its market in Europe and the U.S.

Healthium’sproduct portfolio includes surgical sutures, needles, a patented arthroscopy portfolio, a urology portfolio, hernia meshes, haemostats, gloves, ligation clips, surgical staplers and other wound closure devices. The Company holds or has applied for 60 patents in India and U.S. Its manufacturing facility at Bangalore is registered with US FDA since 2004.

AbGel is a recognized brand in the gelatin sponge categoryand has been used in India since 1980.Healthium aims to further expand the market access of this portfolio using its wide network of hospitals across India.

AbGel is anabsorbablegelatin sponge, manufactured from highly purified neutral gelatin with haemostatic capabilities and is designed to control blood oozing in instances of haemorrhage from multiple small vessels, and is completely absorbed in 4 to 5 weeks with no residue or encapsulation. It is non-toxic, non-allergic, non-immunogenic and non-pyrogenic.

Surgeries may lead to substantial bleeding intra-operatively causing increased morbidity and mortality. AbGel is beneficial in effectively managing this across a wide variety of specialities including abdominal surgery, neurosurgery, gynaecological surgery, ENT surgery, dental surgery and oncosurgery.

Speaking on the acquisition Anish Bafna, CEO and MD, Healthium Medtech, said, “Hemostasis during surgical procedures is an area of concern for surgeons. We are excited to add a brand like AbGel that is a recognized brand ingelatin sponge category and has beencontributing to safer surgeries for over 4 decades. This acquisition strengthens our presence in the category and our commitment to drive value for our customers. We look forward to combining Healthium’s R&D and manufacturing capabilities with the talent and expertise brought by AbGel’s team as we expand access to precision medtech for patients, globally.”

Viral Parekh, Director, SGK Labs added “We are excited to find the right partner in Healthium to take AbGel to the next level. We are confident that with Healthium’s widedistribution network and the additional support from its direct sales force, AbGel will successfully reach, touch and benefit many more lives”.

About Healthium
Healthium is a global player in Medical Devices focused on surgical and post-surgical markets. Healthium is focused on developing and manufacturing quality products to meet the needs of patients and healthcare professionals with a diverse portfolio that includes a patented Arthroscopy range, a full range of Absorbable, Non- Absorbable and specialty surgical sutures, urology portfolio, and wound closure products including Meshes, surgical staplers, ligation clips and Haemostats. Healthium has manufacturing facilities across India and the company holds or has applied for 60 patents in India and the U.S.

HEALTHIUM MEDTECH LTD

(formerly known as Healthium Medtech Private Limited)

472/D, 13th Cross, 4th Phase, Peenya Industrial Area, Peenya Industrial Area Phase IV, Peenya, Bengaluru, Karnataka - 560 058, INDIA

CIN: U03311KA1992PLC013831

contact@healthiummedtech.com

For any queries or complaints write to
care@healthiummedtech.com

Customer care number
+91-80-41868000

DISCLAIMER

“Healthium Medtech Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India. The DRHP is available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, ICICI Securities Limited, CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Nomura Financial Advisory and Securities (India) Private Limited, at www.icicisecurities.com, www.india.clsa.com, www.credit-suisse.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively, and the websites of the stock exchange(s) at www.bseindia.com and www.nseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the RHP / Prospectus, when available. Potential investors should not rely on the DRHP for any investment decision.”

We use cookies to ensure you get the best experience on our website. Click here to view cookie policy